The US$2 million (A$3.2 million) prize will help to accelerate the use of Vaxxas' high-density microarray patch (HD-MAP) technology to administer mRNA vaccines manufactured at UQ's BASE facility.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

The president announced a major AI investment project, which Oracle Chairman Larry Ellison said could be used to cure cancer.

Lougheed, said the findings of the report were “shocking” and that the information it presents to the public is “long overdue ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ... companies move their manufacturing base here to a more friendly country.” ...

Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and Development Authority ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.